Evaxion Biotech (NASDAQ:EVAX) has announced positive one-year data from its Phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, a potential treatment for melanoma.
The data, from a one-year interim analysis of the ongoing Phase 2 trial investigating EVX-01 with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA, in patients with advanced melanoma, demonstrated a 69% response rate in 11 of 16 patients. Additionally, 15 out of 16 patients showed a reduction in tumor target lesions, an immunogenicity rate of 79%, and a positive correlation between Evaxion’s AI-Immunology platform predictions and immune responses induced by the individual neoantigens in the EVX-01 vaccine.
“We are thrilled to present this groundbreaking data, which underscores the significant therapeutic potential of EVX-01,” said Birgitte Rønø, CSO of Evaxion. “Among several promising individual data points, the 69% Overall Response Rate (ORR) is particularly impressive and encouraging. Building on an already strong data package for EVX-01, these new findings strengthen our confidence that we can meaningfully improve treatment options for advanced melanoma.”
Christian Kanstrup, CEO of Evaxion, said, “The clinical findings are another validation of our AI-Immunology™ platform as a leading AI technology for fast and effective vaccine target discovery and design and clearly positions us as a leader in the field of AI immunology. The observed reduction in tumors in 15 out of 16 patients is offering great hope for patients with melanoma. We are looking very much forward to engaging with stakeholders to present the compelling clinical profile of EVX-01 as a transformative personalized cancer vaccine.”
